

# **The role of the atypical chemokine receptor CCX-CKR in progression and metastasis of cancer**

**Yuka Harata-Lee, B.Sc. (Biomed. Sci.) (Hons.)**

Discipline of Microbiology & Immunology  
School of Molecular & Biomedical Science  
University of Adelaide

A thesis submitted to the University of Adelaide  
in fulfilment of the requirements for the degree of  
Doctor of Philosophy

May 2012





**DECLARATION**

I, Yuka Harata-Lee certify that this work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Yuka Harata-Lee, B.Sc. (Biomedical Sc.) (Hons)

2012

## **ACKNOWLEDGEMENT**

It has been a long journey, and I could not have achieved this goal without the help and support from everyone involved in and outside of the lab. I truly feel that I have been really fortunate to have all those people around me throughout my journey.

In the long list of people who have supported me and contributed to my Ph.D., I must first thank my principal supervisor, Prof. Shaun McColl for providing this great opportunity to partake such an exciting project. Thank you for guiding me through the project, particularly when things weren't rolling in the way we expected them to. I have learnt not only scientific knowledge and skills but also problem solving, scientific writing and presentation (although there is still a large room for improvements). It has been a valuable experience working under you and learning from you.

I must also thank my co-supervisor, Dr. Iain Comerford for all the support and patience. Thank you for helping me throughout my Ph.D., particularly with ICCS, designing experiments and, of course, thesis writing. Thank you also for being patient when I had to distract you with millions of questions. Your knowledge and expertise on CCX-CKR, chemokine biology, general immunology and animal work have been invaluable. I have learnt so much from you during the last 6 years (including honours and RA years!). I have also enjoyed those non-scientific conversations we used to have over few drinks...

To Prof. Mark Smyth, my third supervisor, thank you so much for your advice and input to my project. Particularly for performing those experiments we could not otherwise conduct in our lab; all those experiments using immunocompromised mice, and metastasis survival experiments. I really appreciate all the exciting and interesting data you generated for us.

All the members of the McColl lab, past and present, thank you for being wonderful friends and colleagues. Our lab is such a fun place to work because of the diversity of people I worked with and knowledge and skills each of us possesses. I would like to first thank Adrianna for your hard work, which is often underappreciated, but I know the lab would not run in the way it does now without you. Also our senior post-docs, Marina and Manuela, thank you for your valuable advice with your expertise on cancer biology and cancer cell signalling. Particularly Manuela, thank you for always caring for me and for my project. My fellow Ph.D. students, Julie, Wendel, Mark and Matt, thank you for your support and friendships. Julie, you have been a great friend and great colleague. Thank you for doing

---

the Western for me, and thank you for being there when things were a bit rough, it has really been great to have you around. Thank you Mark for doing those IF, they have added some pretty colours (and meaningful data!) to my thesis, and together with Matt, you two have also been great friends and I wish both of you the best for the future. Also to the rest of the McColl lab; Michelle, Kevin, Carly, Sarah B, Ervin, Valentina, and Ursula, and from the past; Sarah H-J, Sharon, Koi, Olivier, Scott, and Brock, thank you all for those cups of coffee, lunches and beers we shared and silly chats which gave me smiles when I needed them the most.

お父さん、お母さん、博士課程の長い道のりを見守ってくれて、本当にありがとうございました。ここまで辿り着けたのも、教授や研究室のみなさん、そして家族のみんなのおかげだと思います。息切れしそうになって、日本に電話して何気ない会話をするだけで、またがんばろうという気持ちになれました。これからも、周りの人への感謝の心を忘れずに、がんばっていこうと思います。And my extended (in-law) family, Omoni and Rebecca, thank you both for being there for me. Those family lunches, dinners and weekend away have been great opportunities for me to relax and not to think about experiments and mice and thesis etc., and they were precious times.

To my dearest husband James, thank you so much for your support for the last 6 years, and thank you so much for your patience. We can now move on and get on with our lives. I know and you know that I could not have done it without you. You are truly the bestest husband in the whole wide world, you are the awesomeness!

**TABLE OF CONTENTS**

DECLARATION..... iii

ACKNOWLEDGEMENT ..... iv

TABLE OF CONTENTS ..... vi

TABLE OF FIGURES ..... ix

LIST OF TABLES ..... xi

ABBREVIATIONS ..... xii

PUBLICATIONS ARISING FROM THIS WORK ..... xiv

ABSTRACT ..... xv

**CHAPTER 1: INTRODUCTION..... 1**

1.1 Overview ..... 3

1.2 Cancer biology ..... 4

1.2.1 Hallmarks of cancer ..... 4

1.2.1.1 Maintenance of growth signals ..... 6

1.2.1.2 Evasion of growth suppressing signals, contact inhibition and apoptosis ..... 6

1.2.1.3 Dereglulation of cell metabolism ..... 7

1.2.1.4 Activation and maintenance of angiogenesis ..... 7

1.2.1.5 Manipulation of immune system..... 8

1.2.1.6 Invasion and metastasis..... 8

1.2.2 Cancer immunoediting ..... 12

1.2.2.1 Elimination..... 13

1.2.2.2 Equilibrium ..... 18

1.2.2.3 Escape ..... 19

1.3 The chemokine family..... 22

1.4 Involvement of chemokines in progression of cancer ..... 27

1.5 Regulation of chemokines by atypical receptors ..... 30

1.5.1 D6..... 35

1.5.2 DARC..... 36

1.5.3 CCX-CKR..... 37

1.6 The research project ..... 39

**CHAPTER 2: MATERIALS AND METHODS..... 41**

2.1 Reagents and materials..... 43

2.1.1 Plasmids ..... 43

2.1.2 Oligonucleotides ..... 43

2.1.3 Antibodies ..... 43

2.1.4 Mice ..... 47

2.1.5 Solutions and buffers ..... 47

2.1.5.1 Basic solutions ..... 47

2.1.5.2 Nuclease-free water..... 48

2.1.5.3 Formaldehyde solutions ..... 48

2.1.5.4 FACS staining buffer..... 48

2.1.5.5 Binding buffer for scavenging assay..... 48

2.1.5.6 PBS/Tween..... 48

---

2.1.5.7 XTT:PMS .....	48
2.1.5.8 Complete 2x Iscove's Modified Dulbecco's Medium (IMDM) .....	49
2.1.5.9 DNA extraction buffer .....	49
2.1.5.10 DNA staining solution .....	49
2.1.5.11 Complete Lysis Buffer .....	49
2.1.5.12 2x Loading buffer .....	49
2.1.5.13 Polyacrylamide gels .....	50
2.1.5.14 TBS/Tween .....	50
2.1.5.15 Digestion buffer .....	50
2.1.5.16 Mouse red cell removal buffer (MRCRB) .....	50
2.1.5.17 Recombinant protein diluent for sequential ELISA .....	50
2.1.5.18 Diluent for sequential ELISA .....	51
2.1.5.19 Lymphocyte restimulation medium .....	51
2.2 Tissue culture and generation of genetically modified cell lines .....	51
2.2.1 4T1.2 cells .....	51
2.2.2 B16 cells .....	51
2.2.3 E0771 cells .....	52
2.2.4 HEK293T cells .....	52
2.2.5 Transfection of 4T1.2 cells .....	52
2.2.6 Lentiviral transduction of B16 cells .....	53
2.3 <i>in vitro</i> assays .....	54
2.3.1 qPCR .....	54
2.3.2 Flow cytometric analysis for chemokine receptors .....	55
2.3.3 Scavenging assay and enzyme linked immunosorbent assay (ELISA) .....	55
2.3.4 Analysis of anchorage-dependent cell growth .....	56
2.3.5 Analysis of anchorage-independent cell growth .....	56
2.3.6 Adhesion assay .....	57
2.3.7 Homotypic adhesion assay .....	57
2.3.8 Invasion assay .....	58
2.3.9 Migration assay .....	58
2.3.10 Anoikis assay and PI staining of DNA extracted cells .....	59
2.3.11 Western blot analysis .....	59
2.4 <i>in vivo</i> assays .....	60
2.4.1 Primary tumour growth and spontaneous metastasis .....	60
2.4.2 Haematogenous metastasis .....	61
2.4.3 Haematogenous metastasis survival assay .....	62
2.4.4 <i>In vivo</i> intravasation assay .....	62
2.4.5 <i>In vivo</i> neutralisation of CCL21 .....	63
2.5 <i>Ex vivo</i> assays .....	63
2.5.1 Preparation of single cell suspensions from tissue .....	63
2.5.2 Sequential ELISA on tissue homogenate supernatants .....	64
2.5.3 Antibody labelling of cell preparations for flow cytometric analysis .....	65
2.5.3.1 Cell surface staining with unconjugated and directly conjugated antibodies .....	65
2.5.3.2 Intracellular cytokine staining (ICCS) .....	65
2.5.3.3 Analysis of flow cytometric data .....	66

---

2.5.4 Immunofluorescence (IF) staining of tissue sections.....	66
2.6 Statistical analysis .....	67
<b>CHAPTER 3: THE EFFECT OF CCX-CKR OVEREXPRESSION ON PROGRESSION</b>	
<b>OF MAMMARY CARCINOMA .....</b>	<b>69</b>
3.1 Introduction.....	71
3.2 Characterisation of 4T1.2 mammary carcinoma model.....	71
3.3 Generation and characterization of CCX-CKR overexpressing 4T1.2 cell lines .....	72
3.4 The effect of CCX-CKR overexpression on progression of 4T1.2 tumours <i>in vivo</i> .....	76
3.5 The effect of CCX-CKR overexpression on host anti-tumour immune response.....	82
3.6 The effect of CCX-CKR overexpression on malignancy of 4T1.2 cells .....	86
3.6.1 Intravasation of CCX-CKR overexpressing 4T1.2 cells.....	86
3.6.2 Adhesion, invasion and migration of CCX-CKR overexpressing 4T1.2 cells.....	88
3.6.3 Resistance of CCX-CKR overexpressing 4T1.2 cells to anoikis.....	91
3.6.4 The effect of CCX-CKR overexpression on EMT of 4T1.2 cells.....	95
3.7 Summary .....	98
<b>CHAPTER 4: THE EFFECT OF DELETION AND KNOCKDOWN OF CCX-CKR ON</b>	
<b>PROGRESSION OF MELANOMA.....</b>	<b>101</b>
4.1 Introduction.....	103
4.2 The effect of CCX-CKR deletion in the host on progression of mammary carcinoma	
and melanoma .....	103
4.3 Generation and characterisation of CCX-CKR knockdown B16 cell lines .....	110
4.4 The effect of CCX-CKR knockdown on B16 melanoma progression <i>in vivo</i> .....	113
4.4.1 Growth of CCX-CKR knockdown B16 tumours in syngeneic mice .....	113
4.4.2 Metastasis of CCX-CKR knockdown B16 tumours in syngeneic mice .....	115
4.5 The effect of CCX-CKR knockdown on anti-tumour immune responses .....	118
4.5.1 The anti-tumour immune responses to B16 subcutaneous tumours.....	118
4.5.2 Anti-tumour immune responses to secondary B16 tumours in lungs .....	129
4.6 The role of CCR7 and CCL21 in CCX-CKR knockdown–mediated enhancement of	
anti-tumour immune responses .....	133
4.7 Summary .....	138
<b>CHAPTER 5: DISCUSSION .....</b>	<b>143</b>
5.1 Introduction.....	145
5.2 Role of exogenously-expressed CCX-CKR on progression and metastasis of cancer	146
5.3 Role of endogenously-expressed CCX-CKR in progression and metastasis of cancer	
.....	155
5.4 Concluding remarks and future perspectives .....	164
<b>CHAPTER 6: REFERENCES.....</b>	<b>167</b>



---

**TABLE OF FIGURES**

Figure 1.1: Hallmarks of cancer. ....	5
Figure 1.2: Stages of tumour metastasis.....	10
Figure 1.3: Characteristics and process of EMT. ....	11
Figure 1.4: Cancer immunoediting.....	14
Figure 1.5: Chemokine signalling and downstream effects.....	26
Figure 1.6: Typical vs. atypical chemokine receptor. ....	32
Figure 1.6: Typical vs. atypical chemokine receptor. ....	33
Figure 2.1: Gating strategy used for the analysis of TILs in tumour homogenate preparation. ....	68
Figure 3.1: Expression of chemokine receptors CCR7, CCR9 and CCX-CKR by 4T1.2 cells.....	73
Figure 3.2: Expression of CCX-CKR by transfected 4T1.2 cell lines.....	74
Figure 3.3: In vitro scavenging of CCL19 by CCX-CKR transfected 4T1.2 cells. ....	75
Figure 3.4: In vitro growth of transfected 4T1.2 cells.....	77
Figure 3.5: Growth and metastasis of CCX-CKR overexpressing 4T1.2 mammary tumours in syngeneic Balb/c mice. ....	78
Figure 3.6: Lung colonisation of CCX-CKR overexpressing 4T1.2 cells via haematogenous route.....	80
Figure 3.7: Levels of CCX-CKR ligands in the CCX-CKR overexpressing 4T1.2 tumour microenvironment.....	81
Figure 3.8: Levels of inflammatory cytokines in the CCX-CKR overexpressing 4T1.2 tumour microenvironment.....	83
Figure 3.9: Levels of tumour infiltrating leukocytes in CCX-CKR overexpressing 4T1.2 tumours.....	84
Figure 3.10: Growth of CCX-CKR overexpressing 4T1.2 tumours in SCID mice. ....	87
Figure 3.11: Intravasation and survival of CCX-CKR overexpressing 4T1.2 tumour cells in blood circulation. ....	89
Figure 3.12: ECM adhesion of CCX-CKR overexpressing 4T1.2 cells in vitro. ....	90
Figure 3.13: Homotypic adhesion of CCX-CKR overexpressing 4T1.2 cells in vitro....	92
Figure 3.14: Invasion through ECM by CCX-CKR overexpressing 4T1.2 cells in vitro.	93
Figure 3.15: Migration of CCX-CKR overexpressing 4T1.2 cells in vitro.....	94
Figure 3.16: Resistance to anoikis by CCX-CKR overexpressing 4T1.2 cells in vitro measured by western blot for pro-apoptotic proteins. ....	96
Figure 3.17: Resistance to anoikis by CCX-CKR overexpressing 4T1.2 cells in vitro measured by DNA extraction and PI staining. ....	97
Figure 3.18: Expression of epithelial-mesenchymal transition (EMT) markers by CCX-CKR overexpressing 4T1.2 cells. ....	99
Figure 4.1: Levels of CCX-CKR ligands in various tissues of CCX-CKR <sup>-/-</sup> mice. ....	105
Figure 4.2: Growth of E0771 mammary tumours and B16 melanoma in syngeneic C57Bl/6 CCX-CKR <sup>-/-</sup> mice. ....	106
Figure 4.3: Lung colonisation of E0771 and B16 cells in C57Bl/6 CCX-CKR <sup>-/-</sup> mice via	

---

haematogenous route. ....	108
Figure 4.4: Levels of CCX-CKR ligands in E0771 and B16 tumour microenvironment in CCX-CKR <sup>-/-</sup> mice. ....	109
Figure 4.5: Endogenous expression of CCX-CKR by mouse cancer cell lines. ....	111
Figure 4.6: Expression of CCX-CKR by transduced B16 cell lines. ....	112
Figure 4.7: In vitro growth of transduced B16 cell lines. ....	114
Figure 4.8: Growth of CCX-CKR knockdown B16 melanomas in syngeneic C57Bl/6 mice. ....	116
Figure 4.9: Levels of CCX-CKR ligands in the CCX-CKR knockdown B16 tumour microenvironment. ....	117
Figure 4.10 Lung colonisation of CCX-CKR knockdown B16 cells via haematogenous route. ....	119
Figure 4.11 Metastatic burden on the lungs bearing CCX-CKR knockdown B16 nodules. ....	120
Figure 4.12 Survival of mice bearing lung nodules of CCX-CKR knockdown B16 cells. ....	121
Figure 4.13 Levels of tumour infiltrating leukocytes in CCX-CKR knockdown B16 tumours. ....	123
Figure 4.14: Immunofluorescent staining of CCX-CKR knockdown tumour sections for tumour infiltrating leukocytes. ....	124
Figure 4.15: Levels of tumour infiltrating leukocytes expressing CCR7 or CCR9 in the CCX-CKR knockdown B16 tumours. ....	125
Figure 4.16: Levels of inflammatory cytokines in the CCX-CKR knockdown B16 tumour microenvironment. ....	127
Figure 4.17: Levels of IFN-γ producing CD8 <sup>+</sup> T cells in CCX-CKR knockdown B16 tumours. ....	128
Figure 4.18: Ratio of M1/M2 macrophages in CCX-CKR knockdown B16 tumours. ....	130
Figure 4.19: Immunofluorescent staining of CCX-CKR knockdown tumour sections for lymphoid tissue markers. ....	131
Figure 4.20: Levels of infiltrating leukocytes in the lungs bearing CCX-CKR knockdown B16 tumour nodules. ....	132
Figure 4.21: Levels of infiltrating leukocytes expressing CCR7 or CCR9 in the lungs bearing CCX-CKR knockdown B16 tumour nodules. ....	134
Figure 4.22: Growth of CCX-CKR knockdown B16 tumours in immunodeficient mice. ....	136
Figure 4.23: Growth of CCX-CKR knockdown B16 tumours in CCL21-neutralised mice. ....	137
Figure 4.24: Growth of CCX-CKR knockdown B16 tumours in CCR7 <sup>-/-</sup> mice. ....	139
Figure 5.1: Proposed mechanisms of CCX-CKR-mediated inhibition of 4T1.2 tumour growth. ....	148
Figure 5.2: Proposed mechanisms of CCX-CKR-mediated activation of the EMT in 4T1.2 cells. ....	154
Figure 5.3: CCX-CKR knockdown tumour microenvironment in CCR7 <sup>-/-</sup> and CCL21-neutralised mice. ....	160

---

**LIST OF TABLES**

Table 1.1: Chemokine nomenclatures.....	23
Table 1.2: Involvement of chemokines in cancer progression and metastasis. ....	28
Table 1.3: Properties of atypical chemokine receptors. ....	33
Table 2.1: Sequence of shRNA used in this study. ....	44
Table 2.2: Sequence of primers used in this study.....	44
Table 2.3: Antibodies and streptavidin conjugates used in this study. ....	45

---

**ABBREVIATIONS**

$\alpha$ MEM	Minimum Essential Medium Alpha
APC	antigen presenting cell
BSA	bovine serum albumin
CCX-CKR	Chemocentryx chemokine receptor
CNS	central nervous system
CTLA	cytotoxic T-lymphocyte antigen
DARC	Duffy antigen receptor for chemokine
DC	dendritic cell
DEPC	diethylpyrocarbonate
DLN	draining lymph node
DMEM	Dulbecco's Modified Eagle Medium
DR	death receptor
DTT	DL-Dithiothreitol
E/F PBS	endotoxin-free phosphate buffered saline
EAE	experimental autoimmune encephalomyelitis
ECM	extracellular matrix
EDTA	ethylenediaminetetraacetic acid
EGFR	epidermal growth factor receptor
ELISA	enzyme-linked immunosorbent assay
EMT	epithelial-mesenchymal transition
FBS	foetal bovine serum
FCS	forward scatter
GAPDH	glyceraldehyde-3-phosphate dehydrogenase
GFP	green fluorescent protein
GOI	gene of interest
GPCR	G-protein coupled receptor
GRK	G-protein coupled receptor kinase
HLA	human leukocyte antigen
HRP	horseradish peroxidase
ICCS	intracellular cytokine staining
IDO	indoleamine 2,3-dioxygenase
IF	immunofluorescence
IFN	interferon
IGF-1R	Insulin-like growth factor-1 receptor
IL	interleukin
IMDM	Iscove's Modified Dulbecco's Medium
KO mice	knockout mice
LMP	low-molecular-weight protein
LN	lymph node
LPS	lipopolysaccharide
mAB	monoclonal antibody
MAPK	mitogen activated protein kinase
MDSC	myeloid derived suppressor cell
MET	mesenchymal epithelial transition
MFI	mean fluorescent intensity
MHC	major histocompatibility complex
MIC	MHC Class I chain-related molecules

---

MMP	matrix metalloproteinase
MRCRB	mouse red cell removal buffer
M $\Phi$	macrophage
NK cell	natural killer cell
NKT	natural killer T cell
NF- $\kappa$ B	nuclear factor- $\kappa$ B
NO	nitric oxide
PARP	poly (ADP-ribose) polymerase
PBS	phosphate buffered saline
PDGF	platelet-derived growth factor
PFA	paraformaldehyde
PI	propidium iodide
PI3K	phosphoinositol 3-kinases
PKC	protein kinase C
PLC	phospholipase C
PMA	phorbol 12-myristate 13-acetate
PMS	N-methyl dibenzopyrazine methyl sulphate
PMSF	phenylmethanesulphonyl fluoride
PNAd	peripheral node addressin
qPCR	quantitative polymerase chain reaction
RAG	recombination activating gene
RG	reference gene
RNAi	RNA interference
ROI	reactive oxygen intermediate
RPLP0	ribosomal protein large P0
SCID	severe combined immunodeficiency
SDS	sodium dodecyl sulphate
SEM	standard error of the mean
shRNA	short-hairpin RNA
SNP	single nucleotide polymorphism
SSC	side scatter
TAM	tumour associated macrophage
TAP	transporter associated with antigen processing
TBS	Tris buffered saline
T <sub>C</sub>	cytotoxic T cell
TCR	T cell receptor
TGF	transforming growth factor
T <sub>H</sub>	helper T cell
TIL	tumour infiltrating leukocyte
TMBS	tumour-bearing mouse serum
TNF	tumour necrosis factor
TRAIL	tumour necrosis factor-related apoptosis-inducing ligand
T <sub>reg</sub>	regulatory T cell
TSP	thrombospondin
VEGF	vascular endothelial growth factor
wt	wildtype
XTT	2,3-Bis(2-methoxy-4-nitro-5-sulphophenyl)-2H-tetrazolium-5-carboxanilideinner salt
ZO	zona occudens

---

## **PUBLICATIONS ARISING FROM THIS WORK**

### *Manuscripts in preparation:*

Harata-Lee Y., Comerford I., Brazzatti J.A., and McColl S.R., The atypical chemokine receptor CCX-CKR accelerates the epithelial-mesenchymal transition of mammary carcinoma.

Harata-Lee Y., Comerford I., Bunting M.D., Li M., Bastow C., Smyth M.J., and McColl S.R., shRNA-mediated knockdown of atypical chemokine receptor, CCX-CKR leads to melanoma rejection through enhanced recruitment of anti-melanoma leukocytes.

### *Conference Proceedings:*

The 37<sup>th</sup> Annual Scientific Meeting of the Australasian Society for Immunology (2007): Oral and Poster Presentation entitled “The Atypical Chemokine receptor CCX-CKR suppresses the progression of mammary carcinoma.”

Australian Society for Medical Research South Australian Meeting (2009): Poster Presentation entitled “The Atypical Chemokine receptor CCX-CKR suppresses the progression of murine melanoma.”

---

**ABSTRACT**

The significance of chemokine receptors CCR7, CCR9 and their ligands CCL19, CCL21, and CCL25 in various types of cancer including mammary carcinoma and melanoma has been highlighted over the last decade. The atypical chemokine receptor CCK-CKR is a high affinity receptor for these chemokine ligands but rather than inducing classical downstream signalling events promoting migration, it instead sequesters and targets its ligands for degradation. Therefore, CCX-CKR has been proposed to regulate chemokine bioavailability *in vivo*. This putative function of CCX-CKR to regulate the levels of pro-tumourigenic chemokines initially led to the hypothesis that local and systemic regulation of chemokine levels by CCX-CKR influences tumour growth and metastasis *in vivo*, and ultimately, targeting of CCX-CKR could be an effective cancer therapy. Three broad approaches were taken to investigate the role of CCX-CKR in tumour progression and metastasis including overexpression of the receptor on tumour cells, deletion from the mouse host and receptor expression knockdown in tumour cells. The results revealed that overexpression of CCX-CKR on 4T1.2 mouse mammary carcinoma cells inhibits orthotopic tumour growth. However, this effect could not be correlated with chemokine scavenging *in vivo* and was not attributed to host adaptive immunity from experiments performed during the course of the current study. On the other hand, overexpression of CCX-CKR on 4T1.2 cells also resulted in enhanced spontaneous metastasis and haematogenous metastasis *in vivo*. *In vitro* characterisation of tumourigenicity of 4T1.2 cells revealed that overexpression of CCX-CKR rendered them more invasive, less adherent to the ECM and to each other and more resistant to anoikis. These are established characteristics of cells which have undergone EMT and indeed, CCX-CKR overexpressing cells showed a typical expression pattern of EMT markers. In contrast, when endogenous expression of CCX-CKR is deleted in the mouse host, growth and metastasis of E0771 mammary carcinoma and B16 melanoma are inhibited, which is accompanied by elevated

levels of CCX-CKR ligands in tumours and relevant naïve tissues from CCX-CKR-deleted mice. Similarly, shRNA-mediated knockdown of endogenous CCX-CKR from B16 melanoma cells leads to the rejection of primary and secondary tumours. This effect is attributed to elevated levels of CCX-CKR ligands and CCR7<sup>+</sup> and CCR9<sup>+</sup> leukocytes in tumour tissues, which resulted in an overall enhancement of the host anti-tumour immune response. Consistent with these observations, growth of CCX-CKR knockdown tumours was comparable to that of control tumours in CCR7-deleted mice indicating host CCR7 dependency of CCX-CKR-mediated rejection of B16 melanoma. Together, findings from this study revealed important insights into the complex role of CCX-CKR in cancer progression and highlights CCX-CKR as a novel target for the development of more effective anti-melanoma therapies and potentially for the treatment of other types of cancer which affect millions of people worldwide.